FDA approval for Novartis' melanoma combo
The FDA has approved Novartis' Tafinlar(dabrafenib) in combination with Mekinist (trametinib) for the adjuvant treatment of BRAF V600E or V600K mutation-positiv...
Insights into the latest developments in CDMO services and manufacturing.
Continue readingExpert perspectives on the evolving needs of injectable therapies and packaging.
Continue readingExploring the latest developments in inhalation technologies, respiratory delivery and sustainability
Continue readingAdvertisement
Advertisement
Advertisement
Advertisement
Advertisement